• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ProMIS Neurosciences Inc. - Common Shares (NQ:PMN)

    15.20 +0.24 (+1.61%)
    Streaming Delayed Price Updated: 12:57 PM EST, Feb 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 6,728
    Open 15.29
    Bid (Size) 15.18 (200)
    Ask (Size) 15.35 (100)
    Prev. Close 14.96
    Today's Range 14.99 - 15.35
    52wk Range 6.270 - 39.75
    Shares Outstanding 32,689,190
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill

    Performance

    YTD
    +113.1%
    +113.1%
    1 Month
    +86.3%
    +86.3%
    3 Month
    +55.8%
    +55.8%
    6 Month
    -3.5%
    -3.5%
    1 Year
    -33.3%
    -33.3%

    More News

    Read More
    Which stocks are moving before the opening bell on Friday? ↗
    Via Chartmill
    News headline image
    ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    Which stocks are experiencing notable movement on Monday? ↗
    Via Chartmill
    News headline image
    Top movers in Monday's session ↗
    Via Chartmill
    News headline image
    The market is filled with gapping stocks in Monday's session. ↗
    Via Chartmill
    News headline image
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    ProMIS Neurosciences Announces Reverse Stock Split
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    EXCLUSIVE: July's 20 Most-Searched Tickers On Benzinga Pro — Where Do Opendoor, Nvidia, Apple Stock Rank? ↗
    Via Benzinga
    News headline image
    ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    What's going on in today's pre-market session ↗
    Via Chartmill
    News headline image
    ProMIS Neurosciences Announces Private Placement Financing
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is ProMIS Neurosciences Inc. - Common Shares publicly traded?
    Yes, ProMIS Neurosciences Inc. - Common Shares is publicly traded.
    What exchange does ProMIS Neurosciences Inc. - Common Shares trade on?
    ProMIS Neurosciences Inc. - Common Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for ProMIS Neurosciences Inc. - Common Shares?
    The ticker symbol for ProMIS Neurosciences Inc. - Common Shares is PMN on the Nasdaq Stock Market
    What is the current price of ProMIS Neurosciences Inc. - Common Shares?
    The current price of ProMIS Neurosciences Inc. - Common Shares is 15.20
    When was ProMIS Neurosciences Inc. - Common Shares last traded?
    The last trade of ProMIS Neurosciences Inc. - Common Shares was at 02/13/26 12:57 PM ET
    What is the market capitalization of ProMIS Neurosciences Inc. - Common Shares?
    The market capitalization of ProMIS Neurosciences Inc. - Common Shares is 496.93M
    How many shares of ProMIS Neurosciences Inc. - Common Shares are outstanding?
    ProMIS Neurosciences Inc. - Common Shares has 497M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.